SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences advances on receiving USFDA's approval for Draximage DTPA

29 Dec 2017 Evaluate

Jubilant Life Sciences is currently trading at Rs. 795.05, up by 24.50 points or 3.18% from its previous closing of Rs. 770.55 on the BSE.

The scrip opened at Rs. 778.95 and has touched a high and low of Rs. 799.75 and Rs. 778.00 respectively. So far 69,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 879.10 on 12-Apr-2017 and a 52 week low of Rs. 600.00 on 25-Oct-2017.

Last one week high and low of the scrip stood at Rs. 808.40 and Rs. 759.80 respectively. The current market cap of the company is Rs. 12,663.00 crore.

The promoters holding in the company stood at 54.02%, while Institutions and Non-Institutions held 24.66% and 21.32% respectively.

Jubilant Life Sciences’ material wholly owned subsidiary - Jubilant Pharma, through one of its wholly owned subsidiaries, has received a Supplemental New Drug Application (sNDA) approval from US Food and Drug Administration (USFDA) for Draximage DTPA powder for solution. Specifically, Draximage DTPA is a kit for the preparation of Technetium Tc99m pentetate injection.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.


Jubilant Pharmova Share Price

891.75 12.80 (1.46%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×